Previous 10 | Next 10 |
home / stock / btai / btai articles
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. Beyond Air posted a quarterly lo...
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program o...
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck ...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% t...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling 1.5% on Wednesday. Following the market opening Wednesday, the Dow traded ...
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shar...
Truist downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) from Buy to Hold, citing significant near-term funding and clinical d...
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ:IBRX) Lifshitz Law PLLC announces investigation into possible securities...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...